Why Did Concordia Healthcare Corp. Shares Fall 50%?

Concordia Healthcare Corp. (TSX:CXR)(NYSE:CXRX) shares have fallen by 50% since September 8th. Is this the opportunity of a lifetime?

| More on:
The Motley Fool

On the morning of September 8th, Concordia Healthcare Corp. (TSX:CXR)(NASDAQ:CXRX) was flying high. It had just announced another big acquisition, one that would increase its earnings per share by 35% in the first year. The U.S.-listed shares opened at US$89, an all-time high.

Fast forward to Friday afternoon, and the shares closed at US$43.90, down more than 50%. So, what exactly happened, and is this a good buying opportunity? We take a look below.

What went wrong?

The bad news started when investors fully digested the new acquisition. Like Concordia’s other purchases, it required a big capital raise, but this one was apparently too much for investors to stomach. The stock fell below US$75 that day.

From there, the shares drifted down further as investors worried about the effects of Concordia’s equity raise. Put simply, a bunch of the company’s shares were about to be sold, and investors got scared this would drive down the stock price. By Friday September 24th, Concordia’s shares were trading for less than US$67.

Then on the following Monday, Democratic lawmakers demanded a subpoena on Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX), one that would have forced the company to release details of recent price increases. The Democrats were reacting to the recent uproar over high drug prices, which has become the number one healthcare priority for American voters.

This made Concordia’s shareholders especially nervous, because 100% of the company’s business is in the United States, and profits primarily depend on drug price increases. Concordia’s stock price dropped by about a quarter that day, closing below US$43.

From there, some big stop-loss orders were triggered, sending the shares well below US$40. Bargain hunters then stepped in, leading to a modest recovery.

Is this a buying opportunity?

There are some serious risks that come with an investment in Concordia. First of all, the company is a serial acquirer, which makes the business difficult to value. And when using traditional financial metrics, the stock is very expensive. Thus, an investment in the company requires a lot of faith in management—not unlike an investment in Valeant.

Furthermore, the United States could pass new legislation to control drug prices. Hillary Clinton has proposed some drastic measures, including a US$250/month limit on out-of-pocket drug costs in health insurance plans. Even more modest steps can have a big impact; for example, Medicare can negotiate lower prices for drugs, or the United States could import more pharmaceuticals from Canada. Mrs. Clinton supports these measures as well.

But at the same time, Concordia shares have clearly fallen way too far, which tends to happen when everyone is selling at the same time. And any new legislation would require approval from Congress, which is far from a given. So, if you’re willing to take some risks, Concordia is worth a small slice of your portfolio.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Benjamin Sinclair has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

Payday ringed on a calendar
Dividend Stocks

3 Dividend Stocks That Pay Me More Than $54.57 Per Month

These three dividend stocks have done me well over the years, so let's look at how much I've gotten in…

Read more »

Golden crown on a red velvet background
Dividend Stocks

Dividend Royalty: 3 Fabulous Stocks to Buy Now for Decades of Passive Income

Rogers Communications stock and Canadian Natural Resources stock could pay you dividends for decades to come.

Read more »

stock analysis
Investing

“GARP” Investing: 3 Can’t-Miss Stocks to Buy Now

goeasy (TSX:GSY) and other low-cost growth stocks could make your portfolio a market beater over the long run!

Read more »

calculate and analyze stock
Investing

My Take: The Best TSX Stock to Buy With $1,000 in March 2024

Here's why Restaurant Brands (TSX:QSR) remains a top TSX stock long-term investors should buy right now.

Read more »

Dividend Stocks

The Top Canadian REITs to Buy in April 2024

For growth and dividends this April, look to these two REITs that have quite the promising present as well as…

Read more »

Woman has an idea
Tech Stocks

Prediction: 1 Stock That Could Trounce the Market 

The TSX has been favouring tech stocks, but not this one. However, it has the potential to trounce the market…

Read more »

Canadian Dollars
Stock Market

Where to Invest $5,000 in April 2024

Do you have some extra cash to spare? Here are five companies to invest $5,000 in next month.

Read more »

Plane on runway, aircraft
Stocks for Beginners

Up 53% From its 52-Week Low, Is Cargojet Stock Still a Buy?

Cargojet (TSX:CJT) stock is up a whopping 53%, nearing closer to 52-week highs from 52-week lows, so what's next for…

Read more »